Waters has introduced a new research use only LC-MS, the SARS-CoV-2 LC-MS Kit, which uses an orthogonal analytical method that directly detects and quantifies SARS-CoV-2 Nucleocapsid (NCAP) peptides that initial studies have shown to yield highly accurate, quantitative results. Waters developed the kit in support of a coalition of academic, commercial and government research scientists. This coalition worked to develop an alternative test method on LC-MS platforms in support of the United Kingdom’s National Health Service (NHS) Test & Trace programme. Their goal was to create a complementary, high-throughput screening method that would also use different reagents to help relieve strain on the PCR reagent supply chain.